Page 45 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) News provided by Share this article Share this article NEWTON, Mass., Feb. 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 165,500 shares of Karyopharm's common stock to 31 newly-hired employees, with a grant date of January 29, 2021.  The stock options were granted as inducement...

Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma -- European Commission Decision Anticipated by April 2021 -- News provided by Share this article Share this article NEWTON, Mass., Jan. 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the conditional approval for NEX...

Share this article LAS VEGAS, Jan. 12, 2021 /PRNewswire/ -- DelveInsight's " Diffuse Large B-cell Lymphoma Market Research Report" report delivers thorough comprehension of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology along with the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The DLBCL market report provides analysis of current Diffuse Large B-cell Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs. Diffuse Large B-cell Lymphoma Mark...

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update -- Unaudited Total Revenues of between $35.0 Million and $36.0 Million for Fourth Quarter 2020 and between $108.0 Million and $109.0 Million for the Full Year 2020 -- -- XPOVIO® (selinexor) Unaudited Net Product Sales of between $20.0 Million and $20.5 Million for Fourth Quarter 2020 and between $76.0 Million and $76.5 Million for the Full Year 2020 -- -- Commercial Launch of XPOVIO in Expanded Multiple Myeloma Indication Fully Underway -- News provided by Share this art...

December 21, 2020 --Oral XPOVIO® Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO® Addressable Patient Population - -- Oral XPOVIO® is Now the Only Approved Multiple Myeloma Drug Indicated as Part of a Once-Weekly Bortezomib Combination Regimen - -- First Multiple Myeloma Drug with a New Mechanism of Action Approved by the FDA in the Second-Line Setting Since 2016 - -- FDA Approval Comes Approximately Three Months Ahead of Target PDUFA Date - SHANGHAI and HONG KONG, Dec. 21, 2020 /PRNewswire/ -- Antengene C...